Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
-
NEW YORK, June 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
-
IV tramadol achieved primary and key secondary endpoints, as well as a clear dose response Initiation of second pivotal Phase 3 trial planned for third quarter of 2018 Management to host conference...
-
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
-
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
-
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
-
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
-
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
-
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today...
-
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate...